All articles by Annabel Kartal Allen

Annabel Kartal Allen

Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel

J&J’s Imaavy posts win in Phase II SLE trial

Johnson & Johnson’s (J&J) new star autoimmune drug, Imaavy (nipocalimab) has demonstrated its disease-modifying potential for systemic lupus erythematosus (SLE)…
Zenas’ stock drops 51% despite lead asset’s Phase III rare disease win

Zenas BioPharma’s lead autoimmune asset, obexelimab, met its primary endpoint in a Phase III trial; however, the data has failed…
BioInvent’s mAb plus Keytruda boosts ORR in mid-stage ovarian cancer trial

BioInvent International’s lead immuno-oncology candidate, BI-1808, has demonstrated promise in the Phase IIa KEYNOTE-D20 study (NCT04752826) in recurrent ovarian cancer.…
Immuneering progresses MAPK inhibitor in lung and pancreatic cancer

Immuneering is set to progress its lead oncology candidate, atebimetinib, to the next stage of clinical development in both first-line…
Parkinson’s stem cell therapy demonstrates promise in Phase II trial

The Hope Biosciences Research Foundation (HBRF) is eyeing a Phase III confirmatory trial for its stem cell therapy after the…

Eli Lilly’s oral GLP-1RA maintains weight loss from injectable drugs

Eli Lilly’s oral glucagon-like peptide 1 receptor agonist (GLP-1RA), orforglipron, has proven its efficacy as a maintenance therapy in patients…
Padcev-Keytruda notches another Phase III win in bladder cancer

A combination of Pfizer and Astellas’ Padcev (enfortumab vedotin) and MSD’s Keytruda (pembrolizumab) has offered significant improvements to patient outcomes…
4DMT’s gene therapy hopeful for cystic fibrosis shows promise in Phase I trial

4D Molecular Therapeutics (4DMT) is pressing ahead with evaluation of its gene therapy, 4D-710, in a Phase II dose expansion…
Immunome seeks GSI inhibitor market entry on Phase III desmoid tumour win

Immunome is seeking US approval for its gamma secretase inhibitor (GSI) for the treatment of desmoid tumours after the drug…
InnoCare’s BTK inhibitor advances to Phase III in SLE

InnoCare Pharma’s orelabrutinib is progressing to a pivotal trial in systemic lupus erythematosus (SLE) after the drug displayed encouraging activity…